Alio develops non-invasive, wireless remote patient monitoring technology, including its SmartPatch device, to support people with chronic conditions such as end stage kidney disease (ESKD) undergoing dialysis. The company’s platform uses artificial intelligence to analyze physiological data and produce actionable insights for targeted interventions. Alio obtained 510(k) clearance in April for its remote patient monitoring platform to intermittently collect physiological data in home-use settings and submitted an additional 510(k) for non-invasive monitoring of hemoglobin, hematocrit, and potassium. The company anticipates an FDA response to that submission in the first half of 2023 and plans a commercial launch following clearance. Alio intends to use new funds to expand its remote patient monitoring technology and scale operations to meet the needs of the chronic care market. The company is led by CEO David Kuraguntla and plans to leverage partnerships with global leaders in kidney care to scale the business. Alio Medical builds wearable monitoring solutions that deliver clinical-grade, real-time data through its primary monitoring platform powered by the SmartPatch, which connects other clinical-grade sensors via proprietary technology. Led by CEO David Kuraguntla, the company is pursuing clinical validation and commercial rollout of its platform. The company will use the Series B funding to conduct clinical studies on expanded indications and to support the platform’s initial commercialization. It also plans to expand its enterprise partnerships within the United States and Europe. The company is headquartered in San Francisco, and the financing included the conversion of all previously issued convertible notes.

Total raised

$38M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2022